NCT05199129

Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients

A Multi-center, Randomized, Double-blinded, Active-Controlled, Parallel, Phase III Study to Evaluate the Efficacy and Safety of HCP1904-3 in Essential Hypertension Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 166 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate of efficacy and safety of HCP1904-3 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.

Detailed description

A Multi-center, Randomized, Double-blinded, Active-Controlled, Parallel, Phase III Study to Evaluate the Efficacy and Safety of HCP1904-3 in Essential Hypertension patients

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	HCP1904-3	Take once daily for 8 weeks orally
DRUG	RLD2001-1	Take once daily for 8 weeks orally

Timeline

• Start date: 2021-11-17
• Primary completion: 2022-09-14
• Completion: 2022-09-14
• First posted: 2022-01-20
• Last updated: 2023-09-22

Locations

1 site across 1 country: South Korea